Theravance $TBPH and development partner Mylan N.V. $MYL reported a successful results from two replicate Phase 3 study evaluating revefenacin (TD-4208) for the treatment of chronic obstructive pulmonary disease (COPD). Both trails met their primary endpoint of a statistically valid improvement versus placebo in trough forced expiatory volume in one second (FEV1) after 12 weeks of treatment with each dose studied (88 mcg once-daily and 176 mcg once-daily). The drug-maker plans U.S. marketing application by end of the next year.